- Gilead Sciences (GILD) is out with top-line data from ION-1, -2, and -3 (Phase 3 sofosbuvir/ledipasvir combo w/ and w/o ribavirin for GT1 HCV).
- Succinct summary from GILD: "Of the 1,518 patients randomized to the 12-week arms of ION-1 and to all arms of ION-2 and ION-3, 95.9% achieved ... SVR12."
- The ribavirin-free arm had fewer adverse events.
- Long story short: The results "demonstrate that a simple, safe and short course of therapy with a single tablet regimen of sofosbuvir/ledipasvir can provide high cure rates among patients with genotype 1 HCV infection, while eliminating the need for both interferon and ribavirin." (PR)
Gilead releases positive data from sofosbuvir/ ledipasvir HCV trials
Dec 18 2013, 09:30 ET